Trade Names:Urecholine- Tablets 5 mg- Tablets 10 mg- Tablets 25 mg- Tablets 50 mg- Injection 5 mg/mL
Trade Names:Duvoid- Tablets 10 mg- Tablets 25 mg- Tablets 50 mg
Trade Names:Myotonachol- Tablets 10 mg- Tablets 25 mgPMS-Bethanechol (Canada)
Stimulates parasympathetic nervous system, increasing tone to muscles of urinary bladder, stimulates gastric motility and tone and may restore rhythmic peristalsis.
Does not cross blood-brain barrier.
5 to 15 min.
60 to 90 min.
1 h, up to 6 h for larger doses.Subcutaneous
Treatment of acute postoperative and postpartum nonobstructive urinary retention and neurogenic atony of the urinary bladder with retention.
Diagnosis and treatment of reflux esophagitis.
Hyperthyroidism; peptic ulcer; latent or active asthma; pronounced bradycardia; AV conduction defects; vasomotor instability; coronary artery disease; epilepsy; parkinsonism; coronary occlusion; hypotension; hypertension; bladder neck obstruction; spastic GI disturbances; acute inflammatory lesions of the GI tract; peritonitis; marked vagotonia. Not used when strength or integrity of GI or bladder wall is in question or in presence of mechanical obstruction, when increased muscular activity of GI tract or urinary tract may prove harmful (eg, after recent urinary bladder surgery, GI resection and anastomosis, possible GI obstruction).
PO 10 to 50 mg 3 times daily to 4 times daily on empty stomach.
Subcutaneous 2.5 to 5 mg at 15 to 30 min intervals for max of 4 doses; then minimum effective dose may be repeated 3 times daily to 4 times daily as needed.
Store tablets at controlled room temperature (59° to 86°F). Keep tightly closed. Avoid storage of injection at less than -4°F and more than 104°F.
Possible toxicity because of additive effects.Ganglionic blocking compounds
Severe hypotension, usually preceded by severe abdominal symptoms.Quinidine or procainamide
Antagonism of anticholinergic effects of bethanechol.
None well documented.
Fall in BP with reflex tachycardia; vasomotor response.
Flushing with feeling of warmth; sensation of heat about face; sweating.
Abdominal cramps or discomfort; colicky pain; nausea; belching; diarrhea; rumbling and gurgling of stomach; salivation.
Bronchial constriction; asthmatic attacks.
Establish baseline BP and pulse and monitor BP, pulse, and voiding patterns. Notify health care provider if urinary retention persists.
Category C .
Safety and efficacy not established.
Some products contain tartrazine, which may cause allergic-type reactions (eg, bronchial asthma) in susceptible individuals.
May occur if bethanechol administration fails to relax urinary sphincter and urine is forced back into renal pelvis.
Abdominal discomfort, salivation, flushing of skin, sweating, nausea, vomiting, low BP, shock, cardiac arrest.
Copyright © 2009 Wolters Kluwer Health.